Payment overview · 2025
General Payments
$197,871.14
504 reported records · 26 companies
Healthcare provider profile · identity verified
Julia Ellen Buchfuhrer, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · DOWNEY, CA · NPI 1093179319
Verified facts
What the public records show
CMS Open Payments records show Julia Ellen Buchfuhrer, D.O. received $197,871.14 in general payments during 2025 across 504 reported records.
Amgen Inc. accounted for 54.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Kevzara, Krystexxa, Prolia, Rinvoq, Tremfya.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Rinvoq by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KRYSTEXXA as an associated drug or biological on 45998 records involving 14548 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Krystexxa by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Prolia by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEVZARA as an associated drug or biological on 5840 records involving 2002 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Kevzara by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Benlysta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tremfya by this doctor in 2024.
Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 4976 records involving 2737 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tremfya by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $106,786.07 | 54.0% | 193 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69,281.42 | 35.0% | 130 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $18,891.98 | 9.6% | 57 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $385.49 | 0.2% | 16 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $358.25 | 0.2% | 19 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $345.04 | 0.2% | 19 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $245.01 | 0.1% | 12 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $225.62 | 0.1% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $181.13 | 0.1% | 8 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $154.77 | 0.1% | 7 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $136.27 | 0.1% | 4 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $135.25 | 0.1% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $122.31 | 0.1% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $116.72 | 0.1% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $92.33 | 0.1% | 3 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $88.16 | 0.0% | 4 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $47.53 | 0.0% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $42.31 | 0.0% | 5 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $38.98 | 0.0% | 1 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $33.21 | 0.0% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.59 | 0.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $30.55 | 0.0% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $29.34 | 0.0% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $26.71 | 0.0% | 1 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $23.75 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.35 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $153,931.00 | 63 |
| Travel and Lodging | $22,642.17 | 68 |
| Food and Beverage | $11,346.13 | 362 |
| Consulting Fee | $9,803.60 | 5 |
| Education | $148.24 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $54,982.00 | 79 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51,050.33 | 72 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $44,092.31 | 90 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $18,891.98 | 57 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $14,774.15 | 14 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $10,018.52 | 33 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $459.70 | 28 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $385.49 | 16 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $337.40 | 18 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $247.57 | 13 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $245.01 | 12 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $225.62 | 5 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $208.66 | 12 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $206.07 | 8 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $181.13 | 8 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $154.77 | 7 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $145.16 | 15 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $136.27 | 4 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $135.25 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $92.33 | 3 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $88.16 | 4 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $87.50 | 3 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $79.97 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.90 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.88 | 4 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $47.53 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $43.17 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $42.31 | 5 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $38.98 | 1 | 2025 |
Source payment records
|
|||||
| HYRIMOZ Normalized: hyrimoz |
Biological | Sandoz Inc. | $33.21 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.91 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $30.59 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $30.55 | 1 | 2025 |
Source payment records
|
|||||
| Gazyva Normalized: gazyva |
Biological | Genentech USA, Inc. | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.85 | 2 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $10.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEVZARA kevzara |
2025 | Kevzara | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KRYSTEXXA krystexxa |
2025 | Krystexxa | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 102 | exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 100 | exact normalized | Medicare Part D |
| TREMFYA tremfya |
2025 | Tremfya | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
100 | 15 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | KRYSTEXXA open payments reported associated product |
CMS Open Payments — General Payments 45998 supporting records · 14548 recipient NPIs · example record 1226871690 |
Krystexxa · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
102 | 67 |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | KEVZARA open payments reported associated product |
CMS Open Payments — General Payments 5840 supporting records · 2002 recipient NPIs · example record 1233195032 |
Kevzara · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 292917 supporting records · 40097 recipient NPIs · example record 1174257364 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 4976 supporting records · 2737 recipient NPIs · example record 1174147664 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diclofenac Sodium | Diclofenac Sodium | 190 | 62 |
| Methotrexate | Methotrexate Sodium | 163 | 58 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 155 | 59 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 122 | 23 |
| Alendronate Sodium | Alendronate Sodium | 103 | 41 |
| Prolia | Denosumab | 102 | 67 |
| Rinvoq | Upadacitinib | 100 | 15 |
| Allopurinol | Allopurinol | 86 | 30 |
| Humira(Cf) Pen | Adalimumab | 80 | 15 |
| Folic Acid | Folic Acid | 65 | 22 |
| Prednisone | Prednisone | 54 | 25 |
| Leflunomide | Leflunomide | 50 | 22 |
| Enbrel Sureclick | Etanercept | 48 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 46 | 15 |
| Kevzara | Sarilumab | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 16 |
| Meloxicam | Meloxicam | 33 | 21 |
| Benlysta | Belimumab | 31 | suppressed |
| Saphnelo | Anifrolumab-Fnia | 28 | suppressed |
| Colchicine | Colchicine | 25 | 18 |
| Cimzia (2 Pack) | Certolizumab Pegol | 23 | suppressed |
| Gabapentin | Gabapentin | 20 | 14 |
| Krystexxa | Pegloticase | 19 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Orencia Clickject | Abatacept | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Tremfya | Guselkumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $197,871.14 · 504 records | Amgen Inc. | AREXVY, BENLYSTA, Belbuca, Bimzelx, COSENTYX, DUPIXENT, ENBREL, EVENITY, Gazyva, HADLIMA, HORIZANT, HYRIMOZ, KEVZARA, KRYSTEXXA, Kineret, LUMRYZ, LUPKYNIS, MOUNJARO, NUCALA, OFEV, OTEZLA, PROLIA, PURIFIED CORTROPHIN GEL, RINVOQ, SIMPONI ARIA, SKYRIZI, SMARTVEST, TALTZ, TAVNEOS, TRELEGY ELLIPTA, TREMFYA, Tymlos, UPLIZNA, WAKIX, XELJANZ, XYWAV, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error